Imetelstat + Azacitidine ± Venetoclax
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1/2Investigator-Sponsored (IMAGINE trial)
Key Facts
Indication
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase
Phase 1/2
Status
Investigator-Sponsored (IMAGINE trial)
Company
About Geron
Geron is a commercial-stage biotech focused on developing and commercializing first-in-class telomerase inhibitors for blood cancers. Its science is grounded in the Nobel Prize-winning discoveries of telomeres and telomerase. With its drug imetelstat now approved in the U.S. for certain myelodysplastic syndromes (MDS) patients and a pivotal Phase 3 trial ongoing in myelofibrosis (MF), Geron is positioned to potentially transform the treatment landscape for several difficult-to-treat myeloid malignancies.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Bisantrene (RC220) | Race Oncology | Phase 2 |